Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2984MR)

This product GTTS-WQ2984MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2984MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2673MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ1482MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ7709MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ11284MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ3510MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ14834MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ8816MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ13870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW